FDA approves clinical trial application of specific CAR-NK therapy FT536 in the treatment of solid tumors

Share This Post

May 2022: FDA approves clinical trial application of specific CAR-NK therapy FT536 in the treatment of solid tumours in a CAR-NK clinical trial. The FDA approved an Investigational New Drug Application in January 2022 for the CAR-NK treatment FT536 to treat individuals with relapsed or resistant solid malignancies. In this trial, patients with advanced non-small cell lung cancer, colorectal cancer, head and neck cancer, gastric cancer, breast cancer, ovarian cancer, and pancreatic cancer will receive FT536 as a monotherapy or in combination with a monoclonal antibody. FT536 (Fate Therapeutics) is an allogeneic, multiple-engineered natural killer (NK) cell treatment produced from induced pluripotent stem cells.

This is a genetically engineered NK cell treatment that expresses a CAR that targets the alpha-3 domains of MICA and MICB, two proteins involved in the major histocompatibility complex class I. Both are stress proteins that are extensively produced in many solid tumours and can overcome shedding to restore tumour immunity mediated by NK and T cells. Overall, FT536 contains four functional modifications: a proprietary CAR targeting MICA and MICB’s 3 domain; a novel high-affinity 158V, non-cleavable CD16 (hnCD16) Fc receptor that enhances ADCC; promotes enhanced NK cells Active IL-15 receptor fusion (IL-15RF); and abrogation of CD38 expression, thereby enhancing NK cell metabolic fitness, persistence, and antitumor function.

We expect that FT536 therapy can obtain positive data as soon as possible in clinical trials of solid tumors, and it will be launched as soon as possible to benefit patients.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Risk of developing secondary tumors following CAR-T cell therapy is minimal - A Stanford Study
CAR T-Cell therapy

Risk of developing secondary tumors following CAR-T cell therapy is minimal – A Stanford Study

CAR-T cell therapy, a groundbreaking cancer treatment, carries a risk of developing secondary tumors. This occurs due to the therapy’s potential to cause genetic mutations or alter the immune system’s regulation. Secondary malignancies can arise from these changes, presenting a significant long-term risk for patients. Continuous monitoring and research are crucial to understanding and mitigating these risks, ensuring safer outcomes for those undergoing CAR-T cell therapy.

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy